Читать книгу Biologics, Biosimilars, and Biobetters - Группа авторов - Страница 45

Several important initiatives are in place in Australia to ensure the health community embraces the full potential of innovator biologics and biosimilars. Within this context, and under the stewardship of NPS MedicineWise, The Biologic and Biosimilar Medicines 2020 Forum was held in 2016, to maximize the opportunities these medicines present to the Australian healthcare system.⁷⁶ The Australian National Medicines Policy provided a framework for the Forum to discuss the opportunities and challenges presented by the availability of both innovator biologic and biosimilar medicines. A broad range of perspectives from research, industry, government, medical, pharmacy, and consumer perspectives were considered. The expanding settings in which innovator biologics and biosimilars may be used was also taken into consideration including hospitals, specialist medical centers, primary care, community pharmacy, and nonclinical environments such as the home. The themes that emerged from the forum included: improving the evidence base; optimizing data capture; pharmacovigilance and naming conventions; and building stakeholder confidence and shared decision‐making through high‐quality information.